Barclays raised the firm’s price target on Universal Health (UHS) to $259 from $257 and keeps an Overweight rating on the shares. The company’s core Q2 results missed estimates, but its EBITDA guidance was still raised $80M, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Universal Health Services Reports Strong Q2 2025 Results
- Universal Health downgraded to Underweight from Neutral at Cantor Fitzgerald
- Universal Health Services Balances Growth and Challenges in Earnings Call
- VOO ETF News, 7/29/2025
- Universal Health’s Mixed Performance and Future Challenges Lead to Hold Rating